Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood
Status:
Recruiting
Trial end date:
2021-09-28
Target enrollment:
Participant gender:
Summary
This study is designed to find if the venoactive drug contained diosmin and hesperidin is
able to work against chronic vein-specific inflammation by changing the level of Monocyte
Chemoattractant Protein 1. This chemokine is involved in the vein wall remodeling in patients
with lower limb varicose veins.
Phase:
N/A
Details
Lead Sponsor:
Pirogov Russian National Research Medical University